CRDF - Cardiff Oncology Inc

CRDF - Cardiff Oncology Inc

https://www.cardiffoncology.com

Hold Momentum: Bearish

Recent News

Powered by Alpha Vantage

Cardiff Oncology to Participate in Three Upcoming Investor Conferences

GlobeNewswire • 2 weeks, 3 days ago • score: -0.02

SAN DIEGO, Aug. 28, 2025 ( GLOBE NEWSWIRE ) -- Cardiff Oncology, Inc. ( Nasdaq: CRDF ) , a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will participate in the three upcoming investor ...

Cardiff Oncology ( CRDF ) Q2 Loss Down 19%

Motley Fool • 1 month, 2 weeks ago • score: 0.11

Cardiff Oncology ( NASDAQ:CRDF ) , a biotechnology company focused on developing therapies for cancer patients with high unmet needs, reported its second quarter 2025 earnings on July 29, 2025. The headline news was the completion of patient enrollment for its crucial Phase 2 clinical trial in ...

Cardiff Oncology ( CRDF ) Reports Q2 Loss, Lags Revenue Estimates

Zacks Commentary • 1 month, 2 weeks ago • score: 0.05

Cardiff Oncology (CRDF) delivered earnings and revenue surprises of -10.53% and -19.33%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

As of 2025-09-10 (Snapshot)

Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops drugs for the treatment of cancer. The company is headquartered in San Diego, California.

52W High

$5.64

52W Low

$1.90

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

1.28

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

-3.66

EV/Revenue (<3 favorable)

136.86

P/S (TTM) (<3 favorable)

264.88

P/B (<3 favorable)

2.46

Ownership

Balanced

Source: Overview

Insiders (1–5% typical)

6.05%

Institutions (25–75% balanced)

39.68%

Shares Outstanding

66,526,000

Float

64,896,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

545,000

Gross Profit (TTM)

-40,863,000

EPS (TTM)

-0.87

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

-122.12%

ROE (TTM) (>15% strong)

-0.92%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

-0.26

Momentum

Bearish momentum

Value

-0.3060

Previous

-0.3291

Trend

Rising

Signal Cross

No cross

As of

Sep. 04, 2025